Subscribe To
Aileron therapeutics presents data at aacr-nci-eortc international conference demonstrating alrn-6924's activity as radioprotective agent in preclinical models of acute radiation-induced toxicity
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy ...
October 7, 2021, 9:22 am
Aileron therapeutics presents data at aacr-nci-eortc international conference demonstrating alrn-6924's activity as radioprotective agent in preclinical models of acute radiation-induced toxicity
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy ...
October 7, 2021, 9:22 am
Aileron therapeutics presents data at aacr-nci-eortc international conference demonstrating alrn-6924's activity as radioprotective agent in preclinical models of acute radiation-induced toxicity
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy ...
October 7, 2021, 9:22 am
New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc
CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...
October 7, 2021, 9:21 am
New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc
CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...
October 7, 2021, 9:21 am
New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc
CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...
October 7, 2021, 9:21 am
Oric pharmaceuticals presents initial clinical data from phase 1b trial of oric-101 in combination with enzalutamide and preclinical data on oric-114 at aacr-nci-eortc
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agen...
October 7, 2021, 8:55 am
Oric pharmaceuticals presents initial clinical data from phase 1b trial of oric-101 in combination with enzalutamide and preclinical data on oric-114 at aacr-nci-eortc
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agen...
October 7, 2021, 8:55 am
Oric pharmaceuticals presents initial clinical data from phase 1b trial of oric-101 in combination with enzalutamide and preclinical data on oric-114 at aacr-nci-eortc
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agen...
October 7, 2021, 8:55 am
Relay therapeutics announces preclinical data that support rly-2608 as the first known allosteric pan-mutant selective inhibitor of pi3kα
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform...
October 7, 2021, 8:50 am
Relay therapeutics announces preclinical data that support rly-2608 as the first known allosteric pan-mutant selective inhibitor of pi3kα
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform...
October 7, 2021, 8:50 am
Relay therapeutics announces preclinical data that support rly-2608 as the first known allosteric pan-mutant selective inhibitor of pi3kα
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform...
October 7, 2021, 8:50 am
Janssen announces novel mechanism of action that shows promise against dengue in data published in nature
BEERSE, Belgium, Oct. 6, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration w...
October 6, 2021, 11:00 am
Janssen announces novel mechanism of action that shows promise against dengue in data published in nature
BEERSE, Belgium, Oct. 6, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration w...
October 6, 2021, 11:00 am
Janssen announces novel mechanism of action that shows promise against dengue in data published in nature
BEERSE, Belgium, Oct. 6, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration w...
October 6, 2021, 11:00 am
New preclinical data for edp-235, enanta's oral protease inhibitor specifically designed for the treatment of covid-19, to be presented at isriv-who virtual 2021 conference: covid-19, influenza and rs
WATERTOWN, Mass.--(BUSINESS WIRE)--New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor f...
October 6, 2021, 8:16 am
New preclinical data for edp-235, enanta's oral protease inhibitor specifically designed for the treatment of covid-19, to be presented at isriv-who virtual 2021 conference: covid-19, influenza and rs
WATERTOWN, Mass.--(BUSINESS WIRE)--New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor f...
October 6, 2021, 8:16 am
New preclinical data for edp-235, enanta's oral protease inhibitor specifically designed for the treatment of covid-19, to be presented at isriv-who virtual 2021 conference: covid-19, influenza and rs
WATERTOWN, Mass.--(BUSINESS WIRE)--New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor f...
October 6, 2021, 8:16 am
Surrozen's inflammatory bowel disease candidate shows encouraging preclinical action
Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD...
October 6, 2021, 7:17 am
Surrozen's inflammatory bowel disease candidate shows encouraging preclinical action
Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD...
October 6, 2021, 7:17 am